Loading organizations...
§ Private Profile · Redwood City, CA, USA
Medical device company developing the AVENTUS Thrombectomy System for venous thromboembolic diseases, focused on efficient single-pass clot.
Inquis Medical, based in Menlo Park and Redwood City, California, develops next-generation thrombectomy technology for venous thromboembolic diseases. Its FDA 510(k) cleared AVENTUS Thrombectomy System offers efficient single-pass clot removal with minimal blood loss, enhancing procedural efficiency. The company has secured over $115 million, including a $40 million Series B in August 2024 led by Marshall Wace, and a $75 million Series C. Investors include ShangBay Capital, Yu Star, EnPointe Ventures, and Versant Ventures (Erik Engelson), with Marshall Wace's Andrew D. Goldberg, MD, on the board. Founded in 2020 by Vahid and Mojgan Saadat, Inquis Medical is preparing for a national commercial launch of its AVENTUS system. Its business model centers on venture-backed medical device company raising funding through equity rounds to develop products, complete clinical trials, gain FDA clearance, and scale commercial adoption.
Inquis Medical has raised $115.0M across 2 funding rounds.
Inquis Medical has raised $115.0M in total across 2 funding rounds.
Inquis Medical has raised $115.0M across 2 funding rounds. Most recently, it raised $75.0M Series C in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $75M Series C | — | — | Announced |
| Nov 1, 2024 | $40M Series B | Andrew Goldberg | AI Fund, Amplify Partners, Conviction Partners, Eclipse Ventures, First Round Capital, Walden International, Bernard Arnault, Drew Houston, Dylan Field, Pierre Lamond, EN Pointe, ShangBay Capital, YU Galaxy | Announced |
Inquis Medical has raised $115.0M in total across 2 funding rounds.
Inquis Medical's investors include Andrew Goldberg, AI Fund, Amplify Partners, Conviction Partners, Eclipse Ventures, First Round Capital, Walden International, Bernard Arnault, Drew Houston, Dylan Field, Pierre Lamond, En Pointe.
Inquis Medical is a Silicon Valley-based medical device company founded in 2020, specializing in next-generation thrombectomy technology for venous thromboembolic diseases like pulmonary embolism (PE) and deep vein thrombosis (DVT).[1][4][5] The company develops the AVENTUS Precision Thrombectomy System, a mechanical thrombectomy platform with integrated navigation, aspiration, blood return, and proprietary TrueClot™ tissue-sensing technology that uses Electrical Impedance Spectroscopy to differentiate blood, clot, and vessel wall in real time, enabling precise clot removal while minimizing blood loss and procedure times.[1][2][3][4] It serves interventional cardiologists, vascular surgeons, and physicians treating high-risk PE patients, addressing unmet needs in speed, precision, and efficiency where traditional devices fall short.[2][4][5][6] Inquis received FDA 510(k) clearance for PE treatment in June 2025, following a successful pivotal IDE trial that demonstrated safety, effectiveness, and rapid right heart strain improvement with no device-related major adverse events.[4][5][6]
Inquis Medical was founded in 2020 in Silicon Valley by a team of seasoned entrepreneurs with decades of experience in medical device development.[1][4] Co-CEOs Vahid Saadat and Mojgan Saadat lead the privately funded company, emphasizing physician partnerships to tackle limitations in clot removal for venous thromboembolic diseases.[1][4] The idea emerged from recognizing gaps in existing thrombectomy tools—such as lack of real-time sensing, inefficient blood management, and procedural complexity—prompting the creation of the AVENTUS system.[2][4] Early traction included completing U.S. pivotal IDE trial enrollment by January 2025, positive trial results presented at SCAI 2025 in May, and FDA clearance for PE in June 2025, validating their patient-centric innovations.[5][6]
Inquis Medical rides the wave of advancing interventional treatments for venous thromboembolism (VTE), the leading cause of vascular death worldwide, affecting millions annually with high PE mortality rates.[5] Timing aligns with rising demand for minimally invasive PE solutions amid growing awareness of intermediate-risk cases needing rapid right heart unloading, fueled by clinical data from trials like AVENTUS IDE.[5][6] Market forces favoring Inquis include FDA-cleared innovations addressing legacy device shortcomings—such as blood waste and imprecision—amid a shift toward smart, sensor-driven medtech in peripheral vascular care.[1][4][6] The company influences the ecosystem by pioneering tissue-sensing thrombectomy, potentially setting standards for PE procedures and enabling broader adoption through physician-validated efficiency.[2][4]
Inquis Medical's rapid path from 2020 founding to 2025 FDA PE clearance positions it for U.S. commercialization and potential global expansion, leveraging trial success and partnerships like Alluvia Studio for marketing.[1][5][6] Upcoming trends like AI-enhanced sensing and blood-conserving tech will shape its trajectory, with AVENTUS likely iterating on trial data for broader indications or next-gen features.[2][6] Its influence may grow by transforming PE care from reactive to precise, outpatient-friendly interventions, solidifying Inquis as a vascular medtech leader amid VTE's persistent threat—every minute and drop truly counting.[5]